metastatic castration-resistant Prostate Cancer(CRPC). Malignant neoplasm of prostate
Conditions
Interventions
The treatment method in this study involves the use of therapeutic radiopharmaceutical Alpha-225Ac-PSMA. Patients with treatment-resistant prostate cancer receive the radiopharmaceutical therapy on th
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Castration-resistant metastatic adenocarcinoma of the prostate should be confirmed by histopathology tests at the time of initial diagnosis If a patient is in the metastatic stage of prostate cancer mCRPC and has cancerous lesions in distant areas, the primary site of the disease is present. Cancerous lesions in imaging studies with 68Ga-PSMA-11 or 99mTc-PSMA-11 may demonstrate a higher uptake of the radiopharmaceutical than the uptake in normal liver tissue over the course of 4 weeks before treatment. The patient may have previously received second-generation androgen deprivation therapies (Enzalutamide, Abiraterone), or it may not have been possible for the patient to receive them. The patient may have received taxane-based treatments, or it may not have been appropriate to treat them with taxanes. The patient has been treated with the beta-emitting radiopharmaceutical 177Lu-PSMA-617. Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2." Patients' GFR should be above 30
Exclusion criteria
Exclusion criteria: Low bone marrow function :Hemoglobin concentration of <? g/dL,platelet count of <??? × ???/L, orwhite blood cell count of <?.? × ???/L), ANS<?.?×???/ Low Kidney function: glomerular filtration rate of less than 30 mL/min/1.73 m? of body surface area;Serum/plasma creatinine?1.5×ULN or creatinin clearance<50 ml/min based on cockcroft-Gault formula Low Liver function is defined(Albumin less than 2.5 g/dL, Billirubin?3×ULN ? ?? ?Alanine aminotransferase (ALT) or aspartate aminotransferase (SAT)?3.?×ULN . Patients who do not have cancer lesions that absorb radioactivity in PET or SPECT imaging Patients whose histology from the sampled tissue indicates sarcomatous/spindle cell/small cell differentiation. Untreated patients with kidney obstruction Patients with active secondary malignancy Patients with Chronic or acute glomerulonephritis Patients who have received chemotherapy, wide-field radiotherapy, and radiopharmaceuticals in the last 8 weeks are excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA level measurement. Timepoint: Before treatment and every four weeks after receiving the radiopharmaceutical. Method of measurement: Blood Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Leila Hassanzadeh
Iran University of Medical Sciences
Outcome results
None listed